AGC Biologics– tag –
-
AGC Biologics Commits Half of New Yokohama Biomanufacturing Plant to Major Long-Term Deal
Megaproject Japan Overview AGC Biologics has secured a significant multi-million dollar, long-term commercial manufacturing contract with an undisclosed pharmaceutical firm for its new Yokohama facility, set to open in 2027. This landmar... -
AGC Biologics Secures Landmark Multi-Hundred-Million-Dollar Deal for Yokohama Facility, Cementing Japan’s Biologics Manufacturing Leadership
AGC Biologics Japan Overview AGC Biologics has secured a multi-year, multi-hundred-million-dollar commercial manufacturing agreement for its new Yokohama facility, slated to open in 2027. This landmark deal dedicates approximately half o... -
Japan Prioritizes Quality in ‘China Plus One’ CDMO Strategy with Over $4 Billion Investment by FUJIFILM Diosynth and Others
BioProcess International USA Overview A BioProcess International article analyzes the 'China Plus One' strategy and biomanufacturing capacity in the APAC region. FUJIFILM Diosynth Biotechnologies has committed over $4 billion to global e... -
Global Pharma and Biotech Firms Intensify Investment in Biologics Contract Manufacturing Market, openPR.com Reports
openPR.com USA Overview Global pharmaceutical and biotechnology companies are significantly increasing their investments in the biologics contract manufacturing (CDMO) market, as reported by openPR.com. FUJIFILM Diosynth Biotechnologies ... -
Market Report: Global Single-Use Bioreactor Market to Surge, Thermo Fisher and AGC Biologics Expand Capacity
GlobeNewswire Global Overview This article summarizes the market research report "Global Single-use Bioreactors Market Forecast to Surge from USD 3.61 Billion in 2025 to USD 15.11 Billion by 2034." The global single-use bioreactors marke... -
Denmark Fortifies Biomanufacturing Leadership with $239M AGC Biologics Investment
GeneOnline デンマーク Overview Denmark is rapidly consolidating its position as a global biomanufacturing powerhouse, attracting substantial investment in its advanced infrastructure. AGC Biologics has committed $239 million to significa... -
Strategic CDMO Partnerships Accelerate in Cell and Gene Therapy Market to Tackle Manufacturing and Cost Challenges
Contract Pharma USA Overview The burgeoning cell and gene therapy (CGT) market is increasingly relying on strategic CDMO partnerships to navigate complex manufacturing and cost challenges. Sponsors are actively seeking CDMOs with special... -
AGC Biologics & Asimov Revolutionize Viral Vector Manufacturing with Single-Plasmid Lentiviral Edge Packaging Cell Line License
MetaphysicalCells Unknown Overview AGC Biologics and Asimov have licensed Asimov's pre-engineered Lentiviral (LV) Edge Packaging cell line, poised to revolutionize viral vector manufacturing. AGC Biologics' Milan facility can now produce... -
AGC Biologics Secures CDMO Contract with Teikoku Seiyaku for Recombinant rhMMP-7 Drug Substance, GMP Production at Chiba Plant
AGC Biologics Japan Overview AGC Biologics has signed a CDMO contract with Teikoku Seiyaku Co. for the microbial drug substance manufacturing of recombinant human matrix metalloproteinase-7 (rhMMP-7) 'KTP-001'. Initial cell bank creation... -
Global Biomanufacturing Leaders Lonza, Fujifilm Diosynth, AGC Biologics Expand CGT & mRNA Capacities
Healthcare Ranking USA Overview Major CDMOs including Lonza, Fujifilm Diosynth Biotechnologies, and AGC Biologics are aggressively expanding global manufacturing capacities for biologics, cell & gene therapies (CGT), and mRNA product...
12